MCID: INT068
MIFTS: 52

Intestinal Disease

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Intestinal Disease

MalaCards integrated aliases for Intestinal Disease:

Name: Intestinal Disease 12 15 17
Intestinal Diseases 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5295
ICD9CM 34 569.9
MeSH 43 D007410
NCIt 49 C26801
SNOMED-CT 67 85919009
ICD10 32 K63.9
UMLS 71 C0021831

Summaries for Intestinal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to inflammatory bowel disease and celiac disease 1, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Zinc and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and colon.

Wikipedia : 74 The gastrointestinal tract (digestive tract, alimentary canal, digestion tract, GI tract, GIT) is an... more...

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure Congenital Intestinal Disease Due to an Enzymatic Defect
Intestinal Disease Due to Fat Malabsorption Intestinal Disease Due to Vitamin Absorption Anomaly
Rare Intestinal Disease

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 33.3 TP53 TFF3 MIR21 ICOSLG GHRL GCG
2 celiac disease 1 31.7 ICOSLG H2AC18 GHRL GCG CCR6
3 gastrointestinal system disease 31.4 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
4 peptic ulcer disease 31.2 TP53 H2AC18 GHRL DEFB4A
5 gastritis 31.1 TP53 GHRL DEFB4A CCR6
6 lymphoma, mucosa-associated lymphoid type 31.0 TP53 SDC1 CCR6 BCL6
7 colorectal cancer 31.0 TP53 TFF3 MIR31 MIR21 MIR199A1 MIR196A1
8 diffuse large b-cell lymphoma 30.9 TP53 SDC1 MIR21 MIR199A1 MIR17 MIR145
9 intestinal benign neoplasm 30.7 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR143
10 lymphoma, non-hodgkin, familial 30.6 TP53 SDC1 MIR21 MIR199A1 MIR196A1 MIR17
11 eye disease 30.6 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR126
12 ovarian disease 30.6 TP53 MIR21 MIR199A1 MIR17 MIR145 H2AC18
13 prostate disease 30.6 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
14 colonic disease 30.6 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
15 colorectal adenoma 30.6 TP53 MIR21 MIR17 APC
16 non-alcoholic fatty liver disease 30.6 MIR31 MIR21 MIR17 MIR126 GCG
17 lymphoma, hodgkin, classic 30.6 MIR21 ICOSLG CCR6 BCL6
18 esophageal cancer 30.6 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR145
19 kidney cancer 30.6 TP53 MIR21 MIR199A1 MIR17 MIR126
20 pulmonary disease, chronic obstructive 30.6 MIR199A1 MIR126 ICOSLG H2AC18 CCR6
21 systemic scleroderma 30.5 MIR21 ICOSLG H2AC18 CCR6
22 coccidiosis 30.5 ICOSLG H2AC18 CCR6
23 cholangitis, primary sclerosing 30.5 MIR145 ICOSLG CCR6
24 endometriosis 30.4 MIR199A1 MIR145 MIR143 MIR126
25 pancreatic cancer 30.3 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
26 idiopathic interstitial pneumonia 30.3 MIR21 MIR199A1 CCR6
27 obsolete: immunoproliferative small intestinal disease 12.2
28 rare intestinal disease 12.2
29 genetic intestinal disease 12.1
30 genetic intestinal disease due to fat malabsorption 12.1
31 congenital intestinal disease due to an enzymatic defect 12.1
32 intestinal disease due to fat malabsorption 12.1
33 intestinal disease due to vitamin absorption anomaly 12.1
34 alpha-heavy chain disease 11.9
35 alpha chain disease 11.8
36 crohn's disease 11.5
37 protozoal dysentery 11.4
38 cystoisosporiasis 11.4
39 short bowel syndrome 11.2
40 diverticulitis 11.2
41 blind loop syndrome 11.2
42 familial adenomatous polyposis 11.2
43 mature b-cell neoplasm 10.9 TP53 SDC1 MIR199A1 MIR196A1 MIR17 ICOSLG
44 bone marrow cancer 10.9 TP53 SDC1 MIR21 MIR199A1 MIR196A1 MIR17
45 glucose metabolism disease 10.9 MIR21 MIR199A1 MIR196A1 MIR17 MIR126 ICOSLG
46 ovary epithelial cancer 10.9 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
47 malignant ovarian surface epithelial-stromal neoplasm 10.9 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
48 biliary tract disease 10.9 TP53 MIR31 MIR199A1 MIR196A1 MIR17 MIR145
49 bile duct disease 10.9 TP53 MIR31 MIR199A1 MIR196A1 MIR17 MIR145
50 upper respiratory tract disease 10.9 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR17

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation, diarrhea, signs and symptoms, digestive, anal or rectal pain

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
3
Copper Approved, Investigational Phase 4 7440-50-8 27099
4
Prucalopride Approved Phase 4 179474-81-8
5
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
6
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
7
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
8
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
9
Lactulose Approved Phase 4 4618-18-2 11333
10
Ibuprofen Approved Phase 4 15687-27-1 3672
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Fidaxomicin Approved Phase 4 873857-62-6
17
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
18
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
19
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
20
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
21
Ondansetron Approved Phase 4 99614-02-5 4595
22
Adalimumab Approved Phase 4 331731-18-1 16219006
23
Simethicone Approved Phase 4 8050-81-5
24 Vedolizumab Approved Phase 4 943609-66-3
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
27
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
28
Racepinephrine Approved Phase 4 329-65-7 838
29
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
30
Infliximab Approved Phase 4 170277-31-3
31
Certolizumab pegol Approved Phase 4 428863-50-7
32
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
37
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
38
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
39 Tocotrienol Investigational Phase 4 6829-55-6
40 Antioxidants Phase 4
41 Hepcidins Phase 4
42 Tocopherols Phase 4
43 Tocotrienols Phase 4
44 Serotonin Receptor Agonists Phase 4
45 Iron Supplement Phase 4
46 Ferric Oxide, Saccharated Phase 4
47 Antiparasitic Agents Phase 4
48 Anthelmintics Phase 4
49 Antiemetics Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 691)
# Name Status NCT ID Phase Drugs
1 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
2 Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
3 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
4 Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding Unknown status NCT01176864 Phase 4
5 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
6 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
7 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
8 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
9 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
10 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
11 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
12 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
13 The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single−Blind, Randomized, Multi-center Study Completed NCT02486536 Phase 4 polyethylene glycol
14 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
15 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
16 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
17 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
18 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
19 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
20 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
21 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
22 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
23 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
24 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
25 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
26 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
27 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
28 Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Completed NCT03833999 Phase 4 Ondansetron 8mg;Lactulose;Placebo oral capsule
29 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
30 Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies Recruiting NCT03866538 Phase 4 Withdrawal of Oral Budesonide
31 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases Recruiting NCT01793831 Phase 4
32 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution;Anti-TNF discontinuation: Physiological saline solution
33 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Recruiting NCT03860012 Phase 4 Folic Acid
34 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
35 A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy Recruiting NCT02334631 Phase 4 High Volume Simethicone;Standard Volume Simethicone
36 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
37 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Active, not recruiting NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
38 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Active, not recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
39 The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial Enrolling by invitation NCT02704624 Phase 4
40 Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease Terminated NCT00205062 Phase 4
41 A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease Terminated NCT02566889 Phase 4 Infliximab
42 Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine Terminated NCT01696942 Phase 4 Cimzia;Mesalamine
43 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
44 Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study Unknown status NCT01496053 Phase 2, Phase 3
45 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation Unknown status NCT01863407 Phase 3 DAM;Normal Saline
46 Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Unknown status NCT02044952 Phase 2, Phase 3 Mesalazine, Tripterygium glycosides
47 Telehealth Enhancement of Adherence to Medication in Pediatric Inflammatory Bowel Disease Unknown status NCT01536509 Phase 3
48 A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Oligosaccharide (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia Completed NCT01017614 Phase 3 Monofer;Iron Sulphate
49 A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain Completed NCT01929044 Phase 3 654-II (anisodamine);Buscopan® (hyoscine butylbromide)
50 A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease Completed NCT00810004 Phase 3 Ferinject

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

19
Intestine

MalaCards organs/tissues related to Intestinal Disease:

40
Small Intestine, Colon, Testes, Liver, Bone, T Cells, Skin

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 4089)
# Title Authors PMID Year
1
Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2. 61
31876919 2020
2
Methamphetamine-induced alterations in intestinal mucosal barrier function occur via the microRNA-181c/ TNF-α/tight junction axis. 61
31862507 2020
3
Metabolomic Analysis of the Liver of a Dextran Sodium Sulfate-Induced Acute Colitis Mouse Model: Implications of the Gut-Liver Connection. 61
32024178 2020
4
High-fat diet-derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damage. 61
31810607 2020
5
Evolutionary changes of an intestinal Lactobacillus reuteri during probiotic manufacture. 61
31746150 2020
6
QTL Mapping of Intestinal Neutrophil Variation in Threespine Stickleback Reveals Possible Gene Targets Connecting Intestinal Inflammation and Systemic Health. 61
31843804 2020
7
[Secondary causes of fatty liver disease - an update on pathogenesis, diagnosis and treatment strategies]. 61
32018285 2020
8
Profile analysis reveals endogenous RNAs regulate necrotizing enterocolitis progression. 61
32036223 2020
9
Fatal intestinal inflammatory lesions in equids in California: 710 cases (1990-2013). 61
31999521 2020
10
Role of Hydrogen Sulfide in Chronic Diseases. 61
31895585 2020
11
Updated phylogenetic analysis of the spike gene and identification of a novel recombinant porcine epidemic diarrhoea virus strain in Taiwan. 61
31538715 2020
12
Increasing prevalence of a fluoroquinolone resistance mutation amongst Campylobacter jejuni isolates from four human infectious intestinal disease studies in the United Kingdom. 61
31999701 2020
13
Meta-analysis of the effects of lidocaine on postoperative reflux in the horse. 61
31290164 2020
14
Predictors for Small Bowel Stenosis in Balloon-Assisted Enteroscopy. 61
31894488 2020
15
Dietary Nutrients Mediate Intestinal Host Defense Peptide Expression. 61
31204774 2020
16
Focal duodenal necrosis in chickens: attempts to reproduce the disease experimentally and diagnostic considerations. 61
31983302 2020
17
Antibacterial activity of cyadox against Clostridium perfringens in broilers and a dosage regimen design based on pharmacokinetic-pharmacodynamic modeling. 61
31962185 2020
18
Development and application of a LC-MS/MS assay for simultaneous analysis of 25-hydroxyvitamin-D and 3-epi-25-hydroxyvitamin-D metabolites in canine serum. 61
31958632 2020
19
Intestinal colonization of genotoxic Escherichia coli strains encoding colibactin and cytotoxic necrotizing factor in small mammal pets. 61
31902483 2020
20
Molecular detection of Cryptosporidium and Enterocytozoon bieneusi in dairy calves and sika deer in four provinces in Northern China. 61
31773309 2020
21
Copper nanoparticles induce zebrafish intestinal defects via endoplasmic reticulum and oxidative stress. 61
31820776 2020
22
Effects of Aluminum on the Integrity of the Intestinal Epithelium: An in Vitro and in Vivo Study. 61
31971835 2020
23
NLRP6 self-assembles into a linear molecular platform following LPS binding and ATP stimulation. 61
31932628 2020
24
Antibodies to Crohn's disease peptide 353 as a diagnostic marker for pediatric Crohn's disease: a prospective multicenter study in Japan. 61
31980893 2020
25
Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. 61
31941109 2020
26
Expression patterns of pcbp gene family members during zebrafish embryogenesis. 61
32007595 2020
27
Development of a high-throughput real-time PCR system for detection of enzootic pathogens in pigs. 61
31752620 2020
28
A novel oligosaccharide isolated from Hericium erinaceus and its protection against LPS-induced Caco-2 cells via the TLR4/NF-κB pathway. 61
31960464 2020
29
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. 61
32013312 2020
30
Impact of air pollution on intestinal redox lipidome and microbiome. 61
31904545 2020
31
Protein-elongating mutations in MYH11 are implicated in a dominantly inherited smooth muscle dysmotility syndrome with severe esophageal, gastric, and intestinal disease. 61
31944481 2020
32
Multi-focal Clostridioides (Clostridium) difficile osteomyelitis in a patient with sickle cell anemia: case presentation and literature review. 61
31699546 2020
33
Butyrate alleviates inflammatory response and NF-κB activation in human degenerated intervertebral disc tissues. 61
31780370 2020
34
Laparoscopy to Assist Surgical Decisions Related to Necrotizing Enterocolitis in Preterm Neonates. 61
31874058 2020
35
Diagnostic findings and long-term prognosis in children with anemia undergoing GI endoscopies. 61
31917169 2020
36
Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review. 61
31268137 2020
37
Dietary Gluten as a Conditioning Factor of the Gut Microbiota in Celiac Disease. 61
31399743 2020
38
Molecular characterization of Cryptosporidium isolates from diarrheal dairy calves in France. 61
31796198 2019
39
A Novel Mouse Model of Enteric Vibrio parahaemolyticus Infection Reveals that the Type III Secretion System 2 Effector VopC Plays a Key Role in Tissue Invasion and Gastroenteritis. 61
31848276 2019
40
Factors that influence treatment-seeking expectations in response to infectious intestinal disease: Original survey and multinomial regression. 61
31818708 2019
41
Radiation-induced intestinal damage: latest molecular and clinical developments. 61
31746639 2019
42
Early life nutrition influences susceptibility to chronic inflammatory colitis in later life. 61
31792267 2019
43
Field study on bovine paratuberculosis using real-time PCR and liquid culture for testing environmental and individual fecal samples implemented in dairy cow management. 61
31563316 2019
44
Mechanisms Underlying Bone Loss Associated with Gut Inflammation. 61
31847438 2019
45
Effects of porcine IL-17B and IL-17E against intestinal pathogenic microorganism. 61
31675522 2019
46
Extract of Lactobacillus plantarum strain 06CC2 induces JNK/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cells. 61
31650040 2019
47
In-Vitro Prebiotic Analysis of Microbiota Accessible Pectic Polysaccharides. 61
31586220 2019
48
Effect of patchouli alcohol on macrophage mediated Helicobacter pylori digestion based on intracellular urease inhibition. 61
31568921 2019
49
Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells. 61
31463771 2019
50
The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. 61
31103793 2019

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1 Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1 Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR145
2 10.07 MIR199A1 MIR145

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TFF3 MIR31 MIR21 MIR199A1 MIR17 MIR143

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 TP53 MIR21 GHRL GCG BCL6
2 positive regulation of protein kinase B signaling GO:0051897 9.84 MIR21 MIR199A1 MIR143 MIR126
3 negative regulation of angiogenesis GO:0016525 9.73 MIR21 MIR145 MIR143 GHRL
4 positive regulation of blood vessel endothelial cell migration GO:0043536 9.7 MIR31 MIR143 MIR126
5 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.65 MIR21 MIR199A1 MIR145
6 positive regulation of histone deacetylation GO:0031065 9.58 TP53 BCL6
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17
8 negative regulation of smooth muscle cell proliferation GO:0048662 9.58 TP53 MIR145 MIR143
9 positive regulation of metalloendopeptidase activity GO:1904685 9.57 MIR21 MIR17
10 angiotensin-activated signaling pathway GO:0038166 9.56 MIR145 MIR143
11 miRNA mediated inhibition of translation GO:0035278 9.56 MIR31 MIR21 MIR17 MIR145
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
13 positive regulation of sprouting angiogenesis GO:1903672 9.54 MIR31 MIR126 GHRL
14 aorta smooth muscle tissue morphogenesis GO:0060414 9.51 MIR145 MIR143
15 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
16 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.46 MIR17 MIR143
17 positive regulation of angiogenesis GO:0045766 9.35 MIR31 MIR21 MIR199A1 MIR143 MIR126
18 positive regulation of vascular endothelial cell proliferation GO:1905564 9.33 MIR21 MIR126 GHRL
19 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143
20 gene silencing by miRNA GO:0035195 9.28 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17

Sources for Intestinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....